Annual CFO
-$23.32 M
+$22.24 M+48.81%
December 31, 2023
Summary
- As of February 8, 2025, OCX annual cash flow from operations is -$23.32 million, with the most recent change of +$22.24 million (+48.81%) on December 31, 2023.
- During the last 3 years, OCX annual CFO has risen by +$2.65 million (+10.22%).
- OCX annual CFO is now -3185.21% below its all-time high of -$710.00 thousand, reached on December 31, 2013.
Performance
OCX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$5.55 M
+$427.00 K+7.14%
September 30, 2024
Summary
- As of February 8, 2025, OCX quarterly cash flow from operations is -$5.55 million, with the most recent change of +$427.00 thousand (+7.14%) on September 30, 2024.
- Over the past year, OCX quarterly CFO has dropped by -$1.78 million (-47.28%).
- OCX quarterly CFO is now -3284.76% below its all-time high of -$164.00 thousand, reached on March 31, 2015.
Performance
OCX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$19.78 M
-$1.78 M-9.90%
September 30, 2024
Summary
- As of February 8, 2025, OCX TTM cash flow from operations is -$19.78 million, with the most recent change of -$1.78 million (-9.90%) on September 30, 2024.
- Over the past year, OCX TTM CFO has increased by +$8.77 million (+30.71%).
- OCX TTM CFO is now -11962.80% below its all-time high of -$164.00 thousand, reached on March 31, 2015.
Performance
OCX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
OCX Cash From Operations Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +48.8% | -47.3% | +30.7% |
3 y3 years | +10.2% | +50.6% | +53.5% |
5 y5 years | -100.2% | +50.6% | +53.5% |
OCX Cash From Operations Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | +48.8% | -47.3% | +58.2% | -9.9% | +56.6% |
5 y | 5-year | -18.3% | +48.8% | -47.3% | +58.2% | -9.9% | +56.6% |
alltime | all time | -3185.2% | +48.8% | -3284.8% | +58.2% | <-9999.0% | +56.6% |
OncoCyte Cash From Operations History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | -$5.55 M(-7.1%) | -$19.78 M(+9.9%) |
Jun 2024 | - | -$5.98 M(+56.1%) | -$18.00 M(-4.5%) |
Mar 2024 | - | -$3.83 M(-13.4%) | -$18.86 M(-19.2%) |
Dec 2023 | -$23.32 M(-48.8%) | -$4.42 M(+17.4%) | -$23.32 M(-18.3%) |
Sep 2023 | - | -$3.77 M(-44.8%) | -$28.55 M(-21.1%) |
Jun 2023 | - | -$6.83 M(-17.7%) | -$36.18 M(-10.9%) |
Mar 2023 | - | -$8.30 M(-14.0%) | -$40.59 M(-10.9%) |
Dec 2022 | -$45.57 M(+26.8%) | -$9.65 M(-15.3%) | -$45.57 M(+6.0%) |
Sep 2022 | - | -$11.40 M(+1.3%) | -$42.98 M(+1.0%) |
Jun 2022 | - | -$11.25 M(-15.3%) | -$42.57 M(+8.1%) |
Mar 2022 | - | -$13.28 M(+87.9%) | -$39.38 M(+9.6%) |
Dec 2021 | -$35.94 M(+38.3%) | -$7.07 M(-35.7%) | -$35.94 M(+2.6%) |
Sep 2021 | - | -$10.98 M(+36.3%) | -$35.02 M(+16.6%) |
Jun 2021 | - | -$8.06 M(-18.1%) | -$30.04 M(+3.8%) |
Mar 2021 | - | -$9.84 M(+60.1%) | -$28.95 M(+11.4%) |
Dec 2020 | -$25.98 M(+31.8%) | -$6.14 M(+2.3%) | -$25.98 M(+3.3%) |
Sep 2020 | - | -$6.00 M(-13.7%) | -$25.14 M(+4.8%) |
Jun 2020 | - | -$6.96 M(+1.3%) | -$23.99 M(+20.7%) |
Mar 2020 | - | -$6.87 M(+29.5%) | -$19.87 M(+0.8%) |
Dec 2019 | -$19.71 M | -$5.31 M(+9.4%) | -$19.71 M(+16.9%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2019 | - | -$4.85 M(+70.8%) | -$16.86 M(+16.3%) |
Jun 2019 | - | -$2.84 M(-57.7%) | -$14.50 M(-7.2%) |
Mar 2019 | - | -$6.72 M(+173.5%) | -$15.61 M(+34.0%) |
Dec 2018 | -$11.65 M(-13.0%) | -$2.46 M(-1.1%) | -$11.65 M(-7.1%) |
Sep 2018 | - | -$2.48 M(-37.3%) | -$12.54 M(-7.3%) |
Jun 2018 | - | -$3.96 M(+43.7%) | -$13.52 M(+5.3%) |
Mar 2018 | - | -$2.75 M(-17.7%) | -$12.85 M(-4.0%) |
Dec 2017 | -$13.38 M(+77.9%) | -$3.34 M(-3.6%) | -$13.38 M(+6.6%) |
Sep 2017 | - | -$3.47 M(+5.8%) | -$12.55 M(+24.1%) |
Jun 2017 | - | -$3.28 M(-0.3%) | -$10.12 M(+17.1%) |
Mar 2017 | - | -$3.29 M(+30.9%) | -$8.64 M(+14.9%) |
Dec 2016 | -$7.52 M(+77.9%) | -$2.51 M(+143.1%) | -$7.52 M(+12.2%) |
Sep 2016 | - | -$1.03 M(-42.8%) | -$6.70 M(-5.0%) |
Jun 2016 | - | -$1.81 M(-16.6%) | -$7.05 M(+13.2%) |
Mar 2016 | - | -$2.17 M(+27.8%) | -$6.23 M(+47.4%) |
Dec 2015 | -$4.23 M(+263.3%) | -$1.70 M(+22.3%) | -$4.23 M(+66.9%) |
Sep 2015 | - | -$1.39 M(+40.9%) | -$2.53 M(+120.7%) |
Jun 2015 | - | -$984.00 K(+500.0%) | -$1.15 M(+600.0%) |
Mar 2015 | - | -$164.00 K | -$164.00 K |
Dec 2014 | -$1.16 M(+63.9%) | - | - |
Dec 2013 | -$710.00 K | - | - |
FAQ
- What is OncoCyte annual cash flow from operations?
- What is the all time high annual CFO for OncoCyte?
- What is OncoCyte annual CFO year-on-year change?
- What is OncoCyte quarterly cash flow from operations?
- What is the all time high quarterly CFO for OncoCyte?
- What is OncoCyte quarterly CFO year-on-year change?
- What is OncoCyte TTM cash flow from operations?
- What is the all time high TTM CFO for OncoCyte?
- What is OncoCyte TTM CFO year-on-year change?
What is OncoCyte annual cash flow from operations?
The current annual CFO of OCX is -$23.32 M
What is the all time high annual CFO for OncoCyte?
OncoCyte all-time high annual cash flow from operations is -$710.00 K
What is OncoCyte annual CFO year-on-year change?
Over the past year, OCX annual cash flow from operations has changed by +$22.24 M (+48.81%)
What is OncoCyte quarterly cash flow from operations?
The current quarterly CFO of OCX is -$5.55 M
What is the all time high quarterly CFO for OncoCyte?
OncoCyte all-time high quarterly cash flow from operations is -$164.00 K
What is OncoCyte quarterly CFO year-on-year change?
Over the past year, OCX quarterly cash flow from operations has changed by -$1.78 M (-47.28%)
What is OncoCyte TTM cash flow from operations?
The current TTM CFO of OCX is -$19.78 M
What is the all time high TTM CFO for OncoCyte?
OncoCyte all-time high TTM cash flow from operations is -$164.00 K
What is OncoCyte TTM CFO year-on-year change?
Over the past year, OCX TTM cash flow from operations has changed by +$8.77 M (+30.71%)